Spinal muscular atrophy (SMA) is an autosomal recessive (AR) neuromuscular disease that is one of the most common lethal genetic disorders in children, with carrier frequencies as high as B1 in 35 in US Whites. As part of our genetic studies in the Hutterites from South Dakota, we identified a large 22 Mb run of homozygosity, spanning the SMA locus in an affected child, of which 10 Mb was also homozygous in three affected Hutterites from Montana, supporting a single founder origin for the mutation. We developed a haplotype-based method for identifying carriers of the SMN1 deletion that leveraged existing genome-wide SNP genotype data for B1400 Hutterites. In combination with two direct PCR-based assays, we identified 176 carriers of the SMN1 deletion, one asymptomatic homozygous adult and three carriers of a de novo deletion. This corresponds to a carrier frequency of one in eight (12.5%) in the South Dakota Hutterites, representing the highest carrier frequency reported to date for SMA and for an AR disease in the Hutterite population. Lastly, we show that 26 SNPs can be used to predict SMA carrier status in the Hutterites, with 99.86% specificity and 99.71% sensitivity.
INTRODUCTION
Spinal muscular atrophy (SMA) is an autosomal recessive (AR) neuromuscular disease that occurs in B1 in 10 000 European births, making it the second most common lethal AR disease after cystic fibrosis in European populations. In US Whites, B1 in 35 are SMA carriers. 1, 2 SMA is caused by the homozygous loss of survival motor neuron 1 (SMN1) gene function due to a deletion or possibly to a gene conversion event in B95% of cases; 3 the remaining 5% of patients have intragenic mutations that inactivate the gene. [4] [5] [6] Affected individuals exhibit progressive muscle weakness and paralysis as a result of degeneration and loss of motor neurons in the spinal cord. Four main types of SMA with a large range of severity have been described. SMA type I, the most severe, typically leads to death within the first 2 years of life, whereas individuals with SMA type IV do not experience symptoms until adulthood. The severity of SMA is modified by multiple factors, with the copy number of the homologous gene SMN2 being the major modifier. 3, [7] [8] [9] The SMN1 gene is located on chromosome 5q13, proximal to a nearly-identical homologous gene, SMN2. SMN2 copy number varies from zero to three copies per chromosome, whereas SMN1 copy number ranges from zero to 42 per chromosome. All SMA patients have at least one copy of SMN2, and no individuals who are null for both SMN1 and SMN2 have been observed. It has been hypothesized, therefore, that the loss of both SMN genes is an embryonic lethal condition. 10 Moreover, a single C4T base substitution in SMN2 disrupts proper splicing, so that the most prevalent SMN2 transcript is missing exon 7 and is therefore unstable, whereas SMN1 produces full-length, functional transcript. However, because SMN2 produces a small amount of full-length transcript that can partially ameliorate the SMA phenotype, SMN2 copy number is inversely correlated with disease severity and considered a modifier of SMA. 11 Carrier screening is technically challenging because the SMA region contains many repeated elements that predispose to rearrangements; as a result, B2% of patients carry de novo deletions that originated in the gametes of a parent with two copies of SMN1. 12 In addition, the high homology between SMN1 and SMN2 complicates interpretation of carrier testing results. Carrier and disease status for SMA is typically determined by direct quantification of SMN1 exon 7 dosage, but this method will not identify carriers of intragenic mutations and carriers with the '2+0' genotype, 1, 12 in which one chromosome has two copies of SMN1 in cis and the other has zero copies.
The more than 40 000-member Hutterite community lives in the northern United States and western Canada, and is divided into three major groups, the Schmiedeleut (S-leut), Lehrerleut (L-leut), and Dariusleut (D-leut). Marriages between the three leuts have been uncommon over the last B90 years, although all members of this founder population descended from fewer than 90 ancestors. 13 SMA had previously been reported in the Hutterites, 14 but the carrier frequency in the population was not known. Therefore, we sought to estimate the carrier frequency for SMA mutations, to determine whether a common founder mutation was responsible for SMA in the Hutterites, and to assess the utility of haplotype-based carrier screening in this population. Here we report the results of these studies in 1415 Hutterites.
SUBJECTS AND METHODS Subjects
The study sample, including one child with SMA and four known obligate carrier parents, was comprised of 1415 S-leut Hutterites from South Dakota, aged 6-93 years at the time of our genetic studies. [15] [16] [17] [18] These individuals are related to each other in a 13-generation pedigree, containing 3673 individuals, all of whom can be traced to 64 common founders. The child with SMA is a boy who had onset of symptoms in the second year of life. Three additional L-leut Hutterites from Montana with SMA were also studied. Two were females with onset of symptoms at 7 months of age and 25 years, respectively; one was male, with onset of symptoms at 16 months of age. All four Hutterites with SMA are still ambulatory (current ages 11, 4, 28, and 4 years, respectively).
Genotyping and analysis of SMA region haplotypes
All subjects were genotyped using the Affymetrix 500k, 5.0 or 6.0 SNP arrays (Affymetrix, Santa Clara, CA, USA). SNPs were excluded from analysis if the call rate was o90%, Hardy-Weinberg Po0.001 (correcting for Hutterite population structure and inbreeding 19 ) or Z5 Mendelian errors were generated. SNPs with minor allele frequency o0.05, or were not present on all three chips were also excluded. A final set of 16 405 chromosome 5 SNPs was used for haplotype analysis.
To identify the haplotype carrying the SMA mutation in the Hutterites, we first used the Runs of Homozygosity function in PLINK, 20 which characterized the extent of homozygosity around SMN1 in one S-leut and three L-leut individuals with SMA. We allowed for a B2 Mb gap in SNP coverage in the SMN1/SMN2 region, because the Affymetrix arrays do not include SNPs in this region. No heterozygous SNPs and only five missing genotypes were permitted within the homozygous stretch; SNPs were required to be present at a minimum density of one SNP every 50 kb (excluding the SMN1/SMN2 region mentioned above).
Phasing of subjects and haplotype-based carrier screening Kong et al 21 showed that if two distantly related individuals share at least one allele identical by state (IBS) at Z1000 consecutive SNPs, one can conclude that the SNPs constitute a haplotype that was inherited identical by descent (IBD). We used this rationale to identify Hutterites who were IBD with the SMA carrier haplotype and thus likely to be carriers of the SMN1 deletion, and to exclude Hutterites who were not IBD with any of the SMA haplotype and thus likely to be noncarriers. Custom Perl scripts were used to identify all subjects in our sample who were IBSZ1 at most or all of the SNPs across the region that was homozygous in the affected subjects. Individuals that were IBSZ1 at Z95% of SNPs in the 22 Mb region were considered to be carriers and the remaining individuals were considered to be noncarriers. Haplotypes in both classes were visually verified for consistency with the SMA haplotype to allow identification of any individuals carrying or lacking a section of the haplotype as a result of a recombination event. Using this approach allowed us to phase the SMA carrier haplotype, when present, in each subject without having to phase the other haplotypes. We termed this method 'pseudo-phasing.'
Carrier screening by qPCR
To determine whether there were SMA deletions on other haplotype backgrounds, we used a quantitative real-time PCR (qPCR) protocol, 22 modified to use RNASP as an internal 2-copy control for each subject in a separate PCR reaction. Using this protocol, we were only able to confidently call genotypes for B600 of the 1335 samples tested, possibly due to the complicated genetic structure of the SMA locus. Therefore, we used these data only as an internal check for contrasting with results of the haplotype studies and to identify individuals for further studies using a competitive PCR assay.
SMN copy number determination by competitive PCR
To confirm carrier statuses determined by the haplotype-based screening method or qPCR, SMN1 and SMN2, copy numbers for a subset of the Hutterites were determined at the Ohio State University Molecular Pathology Laboratory using a competitive PCR assay that directly assesses SMN1 and SMN2 dosage. 23 We used three different criteria to select samples for this test. First, we selected 52 representative subjects from families where the SMN1 copy number, as predicted by the haplotype analysis, was discordant with the copy number predicted by the qPCR assay. Second, we selected 12 subjects from families with small portions of the SMA haplotype and three subjects from families that carry part of the SMA haplotype, but not immediately surrounding the locus itself. Lastly, we selected one unaffected adult who was homozygous for the shared segment.
Minimal haplotype analysis
To determine the minimum number of SNPs required to determine carrier status, a 'minimal SMA haplotype' was selected from the 2066-SNP, 22 Mb SMA haplotype, using lasso regression implemented in the R package glmnet, 24 after choosing the parameters a¼1.0, l¼1.503Â10 À3 , by running a 10-fold cross-validation procedure. K-fold cross validation was used to minimize the effects of overfitting the model to our data. The full data set is randomly divided into K-subsamples; K-1 samples are used to develop the model, and then the remaining subsample is used for validation of the model. Lasso regression uses SNPs as predictors of the phenotype (carrying at least one copy of the SMA mutation), while minimizing the number of SNPs in the model. Genotypes were coded as a single allele dosage value using PLINK, where the value indicated the number of copies of the minor allele. Missing genotypes were substituted with the mean dosage value at that SNP calculated from the entire genotyped population.
RESULTS

Identifying a shared haplotype in affected individuals
We expected the pathogenic mutations in the Hutterites with SMA to be inherited IBD from a common S-leut and L-leut ancestor because of the genetic isolation of the population. Consistent with this expectation, we identified a 22 Mb An eight-generation pedigree connects these four affected individuals to their most recent common Hutterite ancestors, a couple who were born in the 1790s (Figure 1b , individuals I.1 and I.2). The sharing of a 10 Mb haplotype (783 SNPs) between the four affected Hutterites supports a single founder origin for the SMA mutation in both leut. Using a competitive PCR assay, we could determine that all four SMA individuals carried zero copies of SMN1 and four copies of SMN2, indicating that the haplotype carrying the deletion of SMN1 in the Hutterites also carries two copies of SMN2.
Haplotype-based carrier screening Pseudo-phasing of 1414 S-leut Hutterites across the SMA region revealed 177 individuals carrying the majority of the 10 Mb shared haplotype (Supplementary Figure S1) , suggesting a carrier frequency of at least one in eight (12.9%) in the South Dakota Hutterites. The most recent common ancestors of the 177 carriers are three Hutterites who were born in the late 1700s, none of whom are founders of the Hutterite pedigree (not shown). Among the Hutterite founders, 13 are ancestral to all 177 carriers, and any one of these founders could have introduced the mutation into the population.
Carrier status of a representative subset of the subjects was confirmed by competitive PCR, and samples from a representative selection of haplotype-determined noncarriers were confirmed by competitive PCR to have two copies of SMN1 (Supplementary Figure S2) . None of the noncarriers had more than two copies of SMN1, suggesting that the '2+0' genotype is not present in the Hutterite population.
The carrier frequency determined by our haplotype-based method is possibly an underestimate of the true SMA mutation frequency in the Hutterites. One source for undercalling carriers would be recombination events that result in retention of a very small portion of the shared haplotype. We searched for such individuals by examining progressively smaller segments of the haplotype (200, 100 and 50 SNPs) proximal and distal to the SMA locus in subjects who did not share Z95% of SNPs IBSZ1 across the entire full-length haplotype, but who were IBSZ1 at the SNPs immediately surrounding the locus.
We identified 12 individuals who had small segments that were IBS to the shared haplotype. Visual examination of the haplotypes revealed that four individuals (two were first degree relatives) appeared to be carriers who had lost most of the haplotype through recombination events (Figure 2a ) and four others carried most of the shared haplotype, but appeared to have had a recombination event near the SMN1 locus, resulting in the loss of the SMA deletion (Figure 2b) . We also identified four individuals who were IBSZ1 to small portions of the shared haplotype, but we were uncertain as to whether they carried the deletion (Figure 2c ). Competitive PCR assays in these 12 subjects confirmed that the SMN1 dosage in each of these individuals corresponded with the status predicted on the basis of visual examination of their haplotypes, the first group (Figure 2a) were carriers, and the second (Figure 2b ) and third (Figure 2c ) groups were noncarriers. The fact that the third group of individuals are noncarriers indicates that being IBS for o3 Mb of the haplotype is not sufficient to be called a carrier.
Identifying carriers of a de novo SMA deletion A second source of undercalling carriers using the haplotype-based approach is the occurrence of de novo mutations, which have been reported in 2% of SMA cases. 12 In those cases, the mutations would likely occur on a different haplotype and be missed by our study. The qPCR assay 22 revealed a father and two of his children who appeared to be carriers of an SMN1 deletion (Figure 3) , although none carried the SMA haplotype. The competitive PCR assay determined that all three were in fact carriers. Further examination of this family revealed that the haplotype segregating with the deletion in these individuals was also present in other family members who were not carriers by competitive PCR, indicating that a de novo deletion arose in the germline of the paternal grandfather (individual II.1 in Figure 3 ) that was inherited by his son and two grandchildren. Although this was the only de novo mutation identified in this study, we obtained qPCR results for less than half of our sample (594/1335 samples). Therefore, it is possible that more de novo mutations are present in the population and that the carrier frequency estimated by the shared haplotype analysis is a lower bound (carrier frequency of 12.7 versus 12.9%, when including the three additional de novo carriers, for example). We estimate a de novo mutation rate of 8.4Â10 À4 , based on the discovery of one such mutation in 1188 meioses.
Identification of an asymptomatic subject homozygous for the SMN1 deletion Two of the 1415 S-leut individuals in our study were homozygous for the SMA haplotype. One was a child diagnosed with SMA in early childhood, but the other was an ostensibly healthy adult woman who was 41 years old at the time of study. The homozygous deletion of SMN1 in this woman was confirmed by competitive PCR and, as expected, all four of her children were carriers. This asymptomatic woman is homozygous for the entire 22 Mb SMA haplotype, although she is not particularly closely related to the SMA child (kinship coefficient of 0.027 versus the S-leut average of 0.034).
Previous studies have reported asymptomatic relatives of SMA individuals who are homozygous for the SMN1 deletion. 9, [25] [26] [27] [28] [29] The precise genetic modifiers that ameliorate the phenotype have not been determined in most cases, although a single base substitution in SMN2 (c.859G4C) enhances splicing of the gene, enabling it to partially or fully compensate for the lack of SMN1 in some cases. 25 However, the unaffected homozygous woman in our study did not carry this modifier.
Identification of a minimal SMA haplotype
To further explore the utility of SNP genotyping for carrier screening in the Hutterites, we employed lasso regression to select the fewest SNPs (of the 2066 in the shared haplotype) required to accurately determine carrier status. The best model consisted of 26 SNPs that formed a 'minimal SMA haplotype' (Supplementary Table S1 ).
The 26-SNP model correctly predicted carrier status in 1409 of 1415 individuals (99.8%) (Figure 4a ). The three subjects who were carriers of a de novo mutation were predicted by the model to be noncarriers, as expected, because the model will only detect individuals carrying the shared SMA haplotype. Two noncarriers were predicted to be carriers, because they carried most, but not all, of the SMA haplotype (individuals 1 and 2, Figure 4b ). Finally, one additional carrier was predicted to be a noncarrier, because only a very small portion of the SMA haplotype remained after a likely recombination event (individual 3, Figure 4b) . Examination of the full 2066-SNP haplotypes of these three subjects (Figure 4c) shows that all three experienced a recombination event breaking up the SMA haplotype. As a carrier screening test, the minimal SMA haplotype model has a specificity of 99.86% and a sensitivity of 99.71%, which are well within the range of SMA carrier tests using other methods. carriers to be IBSZ1 at the nearest single SNPs flanking the SMN1/ SMN2 locus, individual 2 would have been correctly classified as a noncarrier, increasing the specificity to 99.92%, although the sensitivity of this model remains unchanged.
DISCUSSION
In this study, we report evidence for a single founder origin for SMA in the S-leut and L-leut Hutterites and identify 26 SNPs that predict carrier status with high specificity and sensitivity. We further report a minimum SMA carrier frequency of one in eight in the South Dakota (S-leut) Hutterites, which is the highest ever reported for SMA and the highest carrier frequency reported to date for an AR mutation in the Hutterites of South Dakota. To determine how likely it is that a mutation present in a single Hutterite founder would reach a carrier frequency as high as 12.8%, we performed gene-dropping simulations in the South Dakota Hutterite pedigree. The results of 10 000 trials per founder indicated that the mean probability of a unique mutation originating in one of the 13 founders ancestral to all SMA carriers, reaching this frequency or higher was 0.06 (range: 0.013-0.103).
Earlier studies of SMA reported de novo mutations based on microsatellite haplotype analysis in families of affected individuals. 12, [33] [34] [35] In contrast, we detected a de novo mutation event by contrasting phased-SNP haplotypes to SMN1 dosages determined by qPCR and examining the segregation pattern of the haplotype and mutation in additional close relatives. The segregation of the haplotype and SMN1 deletion in this family indicated that the event occurred during a paternal meiosis, as in most other de novo SMN1 deletions. 12 The de novo mutation rate, m, for SMA in the Hutterites is at least 8.4Â10 À4 , which is similar to the m¼1.1Â10 À4 determined by Wirth et al. 12 The expression of the SMA phenotype in the affected Hutterites is relatively mild and is consistent with the four SMN2 copy number (all Hutterite SMA cases are homozygous for the same shared haplotype (0 SMN1, 2 SMN2 per chromosome)). However, there was clinical variability observed, including one asymptomatic homozygous adult with four SMN2 copies out of 1415 subjects (7.1Â10 À4 ). In addition to SMN2 copy number, other modifying factors have been shown to influence the phenotypic variability of SMA. In fact, there are very rare families in which markedly different disease severity is present in affected siblings with the same SMN2 copy number. In one study, differences in splicing factor abundance allowed more full-length expression from the SMN2 gene and accounted for some of the variability observed between discordant sibs. 26, 36 Another study reported families with unaffected SMN1-deleted females who had increased expression of the X chromosome gene plastin 3 (PLS3) compared with their SMA affected siblings. 9 Plastin 3 is important for axonogenesis and, therefore, was proposed as a protective modifier. It is possible that differential expression of PLS3 is modifying the SMA phenotype in the Hutterites, possibly accounting for the relatively early age of onset in the two affected boys and the milder phenotypes among females (including an asymptomatic woman), all of whom are homozygous for the same haplotype carrying 0 SMN1 and 2 SMN2 genes. Regardless of whether PLS3 is having a modifying role in the Hutterites, the variable expression and penetrance of homozygosity for the SMN1 deletion, together with their remarkably similar environment, diet and lifestyle, support the presence of additional genetic modifiers of SMA segregating in the population.
The American College of Medical Genetics recommends 32 carrier screening for SMA in the general population (carrier frequency of B1 in 35), whereas the American College of Obstetrics and Gynecology (ACOG) recommends screening only for those who request the test or who have a family history of the disease. 37 The particular concerns of ACOG include the low frequency of SMA carriers in the general population and the lack of data on price and cost-effectiveness of a carrier screening program. They also noted that counseling of tested individuals is complicated by the fact that 3-5% of individuals have the '2+0' genotype and will be incorrectly identified as noncarriers. 1, 2, 38 Although the costs and benefits of offering SMA carrier screening to the general population are actively debated, 2,39 the case for offering screening to the Hutterite population is more straightforward for several reasons. First, the high carrier frequency (at least one in eight) would, by itself, justify population screening. Second, previous surveys of attitudes toward cystic fibrosis carrier screen in the Hutterites 40 (unpublished results) indicate that the Hutterites value knowing their carrier status and that many would participate in a voluntary carrier screening program. Finally, the '2+0' genotype appears to be absent in the Hutterites, reducing the potential for false negative results. Therefore, providing education and offering carrier screening is indicated and would likely be welcomed by members of this community.
